execut critic
march three compani coverag report result well
number corpor regulatori updat best pack result abcam
strong cer growth outperform underli market growth rate
manag rais top line cer growth guidanc slightli vectura
morphosi result line number consensu struggl
see clear near-term catalyst share
taken detail look convatec guidanc believ guidanc
organ growth lowest-ev ebit margin achiev
believ share repres good valu recent move outperform
sector perform pt prev see march note
put forecast pt chang indivior vectura morphosi
see page detail indivior pt increas
adjust cautiou revenu profil suboxon film weaker usd
posit outlook row franchis pt vectura move lower
basi push us cautiou revenu
profil wholli own asset morphosi put
mileston payment eu move risk-adjust payment
pt move slightli
shield re-assess data aegis-ckd trial conclud
upon exclud number patient feraccru show statist signific
improv haemoglobin week shield also report ec
decid extend label feraccru includ adult iron defici id
without anaemia broaden address patient popul europ
ibd alon whilst small posit re-engag
regul see number obstacl along way
north american colleagu note number updat read-across
name on-going structur pressur us gener sector drug
price rhetor overhang larg cap pharma name updat dmd
retin space well potenti threat antibodi therapi car-t
takeaway find document
takeaway month page
model review forecast chang page
month ahead trade idea page
versu consensu upcom result page
newsflow north america page
eu investor need know page
takeaway month eu healthcar research
march three compani report result well number regulatori
updat best pack result abcam strong cer growth
outperform underli market growth china particular manag rais
cer revenu growth guidanc even though share look
near close full valu think share perform well given strength top
line growth oper leverag come vectura result
line number consensu struggl still see near-term
catalyst stock could lead re-rat posit data would
certainli help partner still need morphosi result read
posit key pipelin asset posit surviv rate seen previous
on-going prepar us launch number in-lin consensu
guid cautiou outsid remain cautiou
pipelin newsflow particularli higher valu asset
result februari convatec share price appear rang bound
took detail look guidanc us manag guidanc
organ growth third worst sinc becom stand-alone entiti ebit
margin lowest ever achiev histori guid think
guidanc beatabl think execut key go forward see
risk weight upsid view share repres good valu
base peer cash flow analysi move outperform sector
perform pt prev
indivior issu neg litig updat court case alvogen court
found alvogen infring three older patent protect indivior
suboxon film whilst believ blow indivior could potenti leav
film franchis expos risk launch futur competitor
would note fda approv gener yet ii three patent
overcom iii indivior challeng outcom court risk launch bring
tripl damag upon lose appeal
mid-march vectura partner hikma announc updat gener
advair program fda upheld origin decis disput resolut process
request addit clinic endpoint studi push timelin back
compani target re-submiss potenti launch
shield assess data conclud upon exclud
small number patient pre-specifi event remain trial
discret investig patient treat feraccru show statist
meaning respons haemoglobin week addit shield report
ec adopt decis extend label feraccru includ adult
iron defici id without anaemia essenti broaden
address patient popul europ million ibd
alon whilst posit updat give scope continu dialogu fda
think still earli day obstacl along way
exhibit group underli cer growth rate vs growth split
group underli growth rate year
highlight eu healthcar research
convatec execut critic opportun exist
result februari link convatec share price appear rang
bound took detail look guidanc
view manag guidanc organ growth ebit margin
achiev histori guid beatabl manag guid
lowest ever ebit margin compani third worst organ revenu
growth figur sinc becom stand-alone entiti second worst consid
plan product rationalis manag align strategi
opportun benefit beat lower target
constitu revenu growth vs
rais revenu forecast revenu
growth fcst split acquisit currenc organ compar
organ impact misstep product rationalis
ebit chang mute higher cost inflat
invest dilut impact new product etc ebit margin within
manag guidanc ep chang
reflect higher interest cost off-set tax
think ebit margin target allow manag make invest
organ acquisit within lower cost territori current underweight
provid better futur growth opportun
ebit margin histori convatec coloplast
capit market estim compani account
exhibit group underli growth rate pipelin analysi
capit market estim compani account
product conceptphas product indevelopmentr launch plannedr launch ebit margincolo ebit margin
valuat think convatec valuat disconnect peer even
convent cash-flow metric think share repres good valu
believ execut key help bridg gap see also think forecast
lower point rebuild confid begin
keep valuat methodolog peer cash flow analysi pt move
see opportun re-rat possibl
manag beat estim ii peer multipl remain similar level allow
bloomberg capit market estim
ln strong interim come
abcam interim result show strong revenu growth report
cer growth rate outperform underli market growth china stand
particular abcam build immunoassay offer abcam insid
initi see long-term upsid revenu potenti manag rais cer
revenu growth guidanc strong balanc sheet
bullish look updat partnership acquisit
make forecast chang think even though share look near close
full valu share perform well market given strength top line
growth oper leverag come
santhera pharmaceut idebenon ppm meet primari endpoint zero
impact pt
santhera idebenon meet primari endpoint phase trial primari
progress multipl sclerosi ppm trial ppm patient
demonstr differ diseas progress daili idebenon dose
versu placebo two year period outcom although neg
come surpris see littl biolog rational use idebenon ppm
part base case zero impact thesi pt sann
vectura hikma announc updat fda displut resolut
generid advair program fda upheld origin decis request
addit clinic endpoint studi anticip fda decis partner hikma
alreadi start plan new clinic studi patient enrol expect start
come week hikma vectura target re-submiss fda new
data potenti launch us request new studi
come surpris given delay seen far underli complex
mor gr result in-lin posit updat cautiou guid
morphosi result read posit key pipelin asset valu
un-risk compani reiter posit surviv rate seen
previous move ahead us launch overal result in-lin
consensu guid cautiou outsid remain
sidelin pipelin newsflow particularli higher valu asset
stx phoenix ash
shield provid updat aegis-ckd studi follow analysi
data see scope continu dialogu fda shield
assess data aegis-ckd studi initi result conclud
remov small number patient arm pre-specifi event
statist signific respons seen remain patient treat
feraccru versu placebo differ ci
statement speak compani understand pre-specifi event
could led patient withdraw permit studi protocol
discret investig remain studi includ patient
receiv transfus henc increas blood haemoglobin level suppos
control set could open opportun shield work
regul either label extens eu even market access us either within
ckd set perhap use data part applic within ibd
set would still see small chanc stage
hansa announc appoint experienc industri exec sren
tulstrup presid ceo take act ceo ulf wiinberg revert
back formal role chairman sren bring wealth industri experi
includ within rare diseas kidney specif hansa help compani
progress commerci enterpris whilst maintain focu
broaden develop pipelin fund take compani forward
ceo place follow sad untim pass prior ceo gran
arvidson think investor look futur updat us eu
within kidney transplant kt space ii next develop step ide
technolog approv within kt sight
ctec ln execut critic opportun exist
convatec share price appear rangebound post result think new
guidanc achiev even beatabl expect rebas convatec
share trade discount peer spite leader market strong
cash gener see opportun execut critic drive real return
see manag align peer cash flow analysi pt chang
move outperform sector perform
ln result line hold pattern
vectura result broadli line estim consensu albeit
lower materi throughout year strateg review
disappoint invest case chang whilst valuat
look attract price target one could argu neg risk
pass investor confid could take time rebuild struggl still see
near-term catalyst stock could lead re-rat posit data
would certainli help partner still need
indv lighten strike twice alvogen also found infring origin patent
indivior announc court rule alvogen infring
three older patent protect suboxon film whilst view loss court
obviou blow indivior think could potenti leav compani
expos risk launch futur competitor path
circumv three origin patent laid court twice
arguabl make easier other follow howev would note
current fda approv gener drl alvogen henc launch possibl
least one approv ii three patent circumv earliest last
till latest provid increment protect gener must
overcom iii indivior appeal outcom mean launch risk bring
tripl damag anyon launch risk lose appeal
sph updat us silhouett partner discuss conclud come week
sinclair confirm compani regain full us distribut right
silhouett product silhouett instalift silhouett refin silhouett lift march
advanc discuss secur new distribut agreement
silhouett instalift us expect conclud come week perhap
week later first anticip releas line expect
would continu highlight ex-u silhouett sinclair set gener revenu
thank strong in-market growth
product particularli brazil compani gone direct lead
asset ellan high gross margin share trade
ev/sal multipl without us silhouett continu see share
stx feraccru label broaden eu
shield announc european commiss ec adopt decis
extend approv indic feraccru includ treatment adult iron
defici id without anaemia provid feraccru much broader
commerci opportun previous approv market europ
treatment iron defici anaemia adult patient inflammatori
bowel diseas ibd label broaden essenti increas address patient
popul europ million ibd alon posit
step theori open larger market opportun group think
opportun drug switch high-pric hospital-onli
product cheaper much broader focus even primari care asset would
appeal corpor suitor could leverag infrastructur asset
even gener look build benefit low side-effect oral iron pill
model review forecast chang
adjust forecast assumpt cautiou revenu profil
suboxon film increas gener threat product switching/altern
dosag form competit lower valu market currenc weaker usd
posit outlook row franchis continu see strong long term
invest case indivior follow approv launch sublocad note
recent posit newsflow increas reimburs coverag valuat sotp
methodolog unchang target price rise given
adjust sotp model primarili dcf/rnpv franchis use
wacc launch asset termin growth rate beyond
patent life pipelin asset use risk-adjust npv analysi discount rate
termin valu beyond end patent expiri plu industry-standard
risk adjust approv commerci success base product either
nce re-posit small molecul impli return price target support
outperform rate
exhibit summari forecast chang
exhibit summari indivior sotp valuat
year decemb new new changeu ebit normalis valuationmethodologyphaseestim launch daterisk adjust mcents/sh p/shchang last notesuboxon us phase placarbilrnpv phase depot phase assetsrnpv cash fines- exhibit group financi estim
incom statement year decemb market rate market rate rate margin margin margin acquir prefer held profit incom report fd normalis continu fd number group share fd year decemb debt ebitda debt per share yield work nananananananav per share exhibit group financi estim contd
year decemb cash non-cash work cash associ flow cash discontinu share net sheet year decemb plant non current current long term liabil net current deficit newsflow calendar newsflowdevelopmen newsflow recent in-licens newsflowapprov launch
adjust forecast assumpt recent result push
us probabl success cautiou revenu profil
wholli own asset partner econom deal
known continu struggl catalyst vectura invest case albeit
begin see consensu estim come back normal level think neg
newsflow may past compani valuat sotp methodolog
unchang target price come given adjust
remov valu earli stage asset manag
progress given risk associ asset yet approv regul
still launch phase utilis sotp model partner launch asset
utilis npv analysi wacc rate vectura net cash termin valu
beyond vectura patent protect partner pipelin asset use risk-adjust
npv discount rate standard industri associ risk adjust
termin valu beyond vectura patent protect product wholli own
pipelin asset also use rnpv discount rate standard risk
adjust appli termin growth rate provid price
target support sector perform rate
exhibit summari forecast chang
year decemb newchang newchang margin margin margin exhibit vectura valuat overview
productdrug name devic typenovel gener assetpartn indicationpeak sale royalti rate estim launch dateprob successrnpv per sharenpv per share un-risk ultibro eu row indacaterol glycopyrronium us glycopyrronium eu fluticason salmeterol dpi gener sandozcopd devic gener royaltyfluticason formoterol mdi mundi us fluticason salmeterol dpi gener hikmacopd budesonid akita jet novel devic gener drug nonesever adult akita jet abovenonepaediatr othercopd eu budesonid formoterol dpi gener sandozcopd us fluticason gener hikmacopd total asset exparel valu launch portfoliovalu soon launch wholli own assetscommt central costsvalu earli stage risk pipelinecor valuationearli stage skye asset earli stage vectura asset devic sale incl flutiform suppli revenu develop servic exhibit group financi estim
incom statement year dec rate technolog licens rate servic devic sale product rate product rate rate margin develop cost margin margin intang held profit incom report fd normalis continu fd number group share fd year dec debt ebitda debt per share yield work per exhibit group financi estim contd
year dec cash non-cash work cash associ flow cash discontinu share net sheet year dec plant non current current long term current deficit newsflow calendar yearresult pre-clos product newsflowscip initi jan june/juli jan june/juli product tripl phase readout submissionproduct read eu top-line data us top-line data file us potenti approv launch us
adjust forecast assumpt recent result account research
incom partner addit adjust exchang rate bring
revenu prev assum mileston payment un-
risk secur commerci partner eu move
potenti mileston payment risk-adjust
sinc think less like sign partner multipl myeloma given on-going
litig ii competit space iii morphosi decis develop
asset partner found adjust bring revenu
previou prev make chang tremfya
total sale although forecast line compani report
make minor adjust within region account faster uptak us
slower eu significantli increas central cost spent
next year account launch prepar us given
compani confirm intent launch us spend
remain unchang within guidanc get clariti develop plan
front line current includ
sotp primarili rnpv valuat morphosi aim valu major asset
group whether partner proprietari ascrib valu underli
technolog valuat suggest fair valu per share support
under-perform rate belief near-term regulatori catalyst
r/r dlbcl alreadi account whilst see near-term neg catalyst
unless delay also see limit upsid unless partner found
proprietari asset could take time ii platform deliv new pipelin
asset view risk/reward longer worthwhil data
near-term posit alreadi price think investor consid
valuat broken valu pipelin asset add cash
tax loss commit arriv core valuat ascrib valu
antibodi platform reach price target
exhibit summari forecast chang
year decemb newchang newchang partner exhibit group financi estim
incom statement year dec rate nananananananaproprietari rate nananananananadirect rate rate margin cost cost margin margin acquir held profit incom report fd normalis continu fd number group share fd year dec debt ebitda debt per share yield nanananananananet work per exhibit group financi estim contd
year dec cash non-cash work cash associ flow cash discontinu share net sheet year dec plant non current current long term current deficit
healthcar valuat tabl sector perform chart
price market close march bst
denot act broker
capit market estim factset price inform
companytickerrecupsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate spec spec medic abhmed-omoutperform spec seknanananananananananananahorizon discoveryhzd-lonsector perform spec biopharma molecular partnersmoln-swxoutperform spec spec therapeuticsstx-lonoutperform spec exclud cureti salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan march
jan
jan march
jan march
jan march
jan march
share exhibit coverag perform versu peer wider sector
jan march
jan march
jan march
medicalnmc dechra pharmaceuticalsindiviorabcameco anim groupudg care publiccv groupgenusi pharmaclinigen groupcaretech holdingsconsort medicalsmith nephewmorphosysfts share price indexastrazenecastoxx europ price indexmolecular partnersglaxosmithklinecambian groupbtgshirehorizon discoveri groupvectura grouphikma pharmaceuticalsspir care gp sinclair pharmabenchmark holdingscircassia medicalnmc dechra pharmaceuticalsindiviorabcameco anim groupcaretech holdingsi pharmagenusudg care publicmorphosyscambian groupclinigen groupcv grouphorizon discoveri groupfts share price indexsmith nephewastrazenecaglaxosmithklinestoxx europ price indexbtgconsort medicalshiremolecular partnersspir care gp benchmark holdingscuretishikma pharmaceuticalssinclair pharmavectura groupcircassia dechra pharmaceuticalshansa medicalmorphosysabcamcambian groupianc pharmaindiviorgenusudg care publicclinigen groupcaretech holdingsbtgastrazenecasmith nepheweco anim groupconsort medicalhorizon discoveri groupmolecular partnersstoxx europ price indexfts share price indexcuretiscircassia pharm glaxosmithklinecv groupconvatec groupshirebenchmark holdingsspir care gp hikma pharmaceuticalsvectura groupsinclair pharmavernalisshield month ahead trade idea
look april result cureti sinclair pharma well
trade updat btg also anticip result circassia
trade updat look updat us approv process
earli stage asset repneu instanc ii visibl potenti crofab competitor
sinclair pharma launch gener zytiga us iii contribut
roxwood acquisit iv progress varithena repneu consist prior
trade updat also anticip see point rang revenu
come instanc mid-point toward upper end
revenue/ebitda/ep estim ahead
consensu in-lin
latest note btg equal risk reward zytiga risk crystallis
year caution outlin valu build im divis repneu
varithena provid division gross profit growth key
downsid risk estim crofab competitor launch potenti ebit impact
much uspto rule zytiga patent
go result look updat tudorza sale us ii
time releas full detail duaklir phase result nda submiss
well iii fund situat
revenue/ebitda/ep estim slightli consensu
revenu line factset higher ebitda ep consensu come
respect believ differ could due
 spend model across street az deal
end last year circassia partner astrazeneca announc posit top-lin result
ascent phase post-market studi tudorza patient
moder sever chronic obstruct pulmonari diseas copd document
cardiovascular risk factor link see posit circassia
tri return tudorza growth us septemb circassia announc
posit top-lin result duaklir phase studi copd mention
analyst call full detail releas medic meet us
link
cureti result less focus number apart cash posit
on-going question fda approv applic
unyvero platform lrt cartridg
februari cureti guid revenu cash cash
equival exclud vat refund receiv januari
compani issu statement expect near-term decis de novo
request unyvero system unyvero lrt cartridg
result look updat new partnership distribut
silhouett product rang post regain right back thermi march
ii discuss extend debt facil iii launch strategi ellan
brazil post approv januari ahead prior expect
result revenue/ebitda/ep estim line consensu
factset consensu lower ebitda ep
whilst situat us gone accord plan think manag
deserv credit face issu tri salvag product rather
let brand deterior would continu highlight ex-u silhouett sinclair
look set gener revenu thank
strong in-market growth product particularli brazil compani
gone direct lead asset ellan high gross margin
share trade ev/sal multipl without us silhouett continu
see share fundament under-valued
prior result recent updat bring back right
silhouett thermi link move us unexpect
factor recent share price arguabl weak sinc trade updat
potenti catalyst timet coverag coverag peer
exhibit potenti catalyst timet coverag coverag peer
note indic project result releas date
stockaprilmayjuneabcam thermo fisher result apr result may biorad result may result apr result apr result apr baxter result tbc result tbc result may integra lifesci result may tbc btgye trade updat apr varian medic system result apr result may preliminari result tbc gsk result apr result may result may medicalgerresheim result apr consort ye trade updat tbc aptar result apr recipharm result apr result may result tbc convatec result apr result may coloplast result may smith nephew result may result may curetisdechra lilli result apr result may phibro result may medicalhorizon discoveri thermo fisher result apr result may biorad result may tbc result may drl gener court case orexo result apr result may camuru result may partner result apr novarti result apr roch result apr result may result apr gsk result apr roch result apr phase data ra tbc initi phase atop dermat tbc santherasarepta result apr result may therapeut sinclair preliminari result apr result may gsk result apr result may decis fda unyvero devic result april qiagen result may feedback fda meet track statu result april tbc argenx result may post meet fda
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
note indic limit number contribut consensu data
factset capit market estim
stockmetricconsensu fcst fcst fcst pharmacureti march yeapril yebtgcircassia consort medicalhorizon discoveri newsflow item north america
north american colleagu believ key newsflow revolv around
on-going structur pressur us gener sector potenti strategi larg cap
pharma unlock valu time patent cliff drug price rhetor overhang
larg cap pharma name updat dmd retin space well
potenti threat antibodi therapi car-t
pressur us
vectura circassia
celgen go privat
randal sever compani coverag univers report month
feedback reflect on-going structur pressur us gener sector
laboratori gener revenu declin q-o-q result
highlight slower growth us consum franchis addit georg comment
recent gener backlog data releas fda reason
fda continu work backlog clear drug market entri may
pressur price potenti revers previou sign moder
brian analys
idea celgen go privat value-cr step
sharehold view celgen uniqu situat strong near-term cash
flow pipelin movement overshadow loom revlimid patent cliff
whilst would like provid upsid current sharehold insul versu medium-
term volatil transit period post-revlimid busi model leverag
buyout rare would like involv creativ structur consortium
pe firm strateg investor instanc big pharma joint ventur
overhang indivior
follow press confer opioid epidem us presid trump
pledg set new polici propos aim lower prescription-drug cost brian
report despit improv investor toler drug price rhetor recent
speech could gener near-term overhang large-cap pharma name link
medium-term product perform
increas minim
posit biomup
glenn novarro brandon henri host doctor day chicago spinal
orthopaed cardiac surgeon well expert surgic robot cardiac
surgeon expect increas transcathet aortic valv replac tavr
procedur practic earli day biomup us commercialis
hemoblast applic minim invas surgeri key featur asset
posit underli growth procedur posit
clinic hold solid
keep threat gene
therapi santhera
idebenon bay
brian comment news clinic hold due safeti
place gene therapi studi dmd ignit see posit read-
across santhera back news highlight competit gene
therapi still earli stage challeng clinic develop unknown safeti
risk continu track develop sarepta gene therapi
programm whether differ vector use safer
posit fda feedback
neg santhera
doctor day car-t
highlight potenti threat
contrast see recent posit fda feedback sarepta file acceler
approv golodirsen slight neg santhera upcom ind fill
idebenon even though idebenon directli compet golodirsen
highlight fda review process in-lin updat guidelin
publish last month detail import dystrophin level endpoint
surrog acceler approv overal remain posit idebenon
potenti clinic benefit howev given differ mode action current
avail data less optimist posit outcom fda year
without data sidero trial avail
rbc us healthcar team host day chicago includ kol car-t
reiter slow high threat car-t therapi see read-across
morphosi also demonstr impress efficaci compar
current approv therapi think compet directli car-t efficaci
still open question though car-t compet morphosi
roch polatuzumab given asset achiev high efficaci compar
current avail therapi safeti conveni price
regn eylea result
moln abicipar
kennen comment eylea posit panorama studi non-prolif
diabet retinopathi npdr patient although long-term potenti see
posit read-across molecular partner allergan asset abicipar
demonstr could also develop retin diseas approv
sinc mechan action eylea
exhibit stock cover dougla miehm
titl link note
design iaip plu thought
pend plasminogen approv
pli receiv rare pediatr diseas design iaip overal view news increment posit pli continu
highlight clinic progress compani make compani second pediatr design plasma-deriv
therapeut first design grant ryplazim plasminogen
quarter expect
await outlook call
crh report result after-market-clos today total revenu estim
consensu anesthesia manag crh-am revenu ahead
forecast product sale revenu line vs forecast
ahead expect
outlook consist previou
crh report result yesterday close quarter ahead street estim although
compani provid financi guidanc reiter previou commentari regard chang payor mix
suggest maintain pace acquisit previou period
 focu upcom mileston
onc report result today believ investor focu remain compani progress toward secur anoth
commerci partnership subsequ begin ph registr studi anticip reolysin launch late
continu view onc attract risk/reward basi given likelihood licens deal year
takeaway day road
opportun spend day valeant manag cfo paul herendeen head ir arthur shannon svp
treasur linda lagorga toronto topic discuss includ leverag long-term outlook manag
thought capit structur
preview uncertainti
report result march market close confer call next morn et believ
investor focu futur geting partnership ii manag expect
anticip
aurinia report full-year result earlier today market close confer call manag reiter
timelin aurora trial expect enrol complet end data read-out late
result line guidanc
novelion report result follow yesterday close revenu consist guidanc last
reiter report light result believ focu remain key issu remain overhang
compani
result await data
clinic mileston
abivax report result real surpris gener compani reiter timelin
outlin previous clinic program near-term await result second cohort trial
specif data around gi hiv reservoir avail first cohort
indic provid final addit inform respons fda support extend claim sterizon
includ termin steril duodenoscop submiss includ data modifi leak test experi
test confirm lack fluid ingress occur distal end cap devic along real-world data
crh complet first acquisit
louisiana size line recent
earlier today crh announc acquisit interest louisiana-bas anesthesia practic practic
estim annual revenu estim crh acquir busi ebitda sharehold
estim ebitda sharehold price target remain account acquisit effect
titl link note
line quarter sentiment unlik
report result even essenti line estim consensu total revenu
vs forecast consensu factset estim gross profit margin
forecast
littl chang view
result essenti line estim surprisingli focu quarter
compani outlook rather report result prepar sell directli end-us first time
 result estim
ahead consensu
dr report revenu vs estim last year consensu factset
estim revenu grew rel revenu estim albeit consensu
view result surpris given season strength usual observ along strong perform
peer group cap
overshadow uniti
impair mean
result morn consensu estim share come pressur sinc releas
believ attribut yoy ebitda declin impair charg associ time
impair rather charg surpris us importantli believ leav littl room error
exhibit stock cover randal stanicki
titl link note
still track cc et
ipxl report revenu million consensu million ebitda million in-lin us
consensu result driven miss gener partial off-set consensu specialti sale driven rytari quarter-
over-quart basi gener revenu declin full-year revenu revenu project
million provid ipxl file base incom calls/quest focu combin outlook
come post-deal close amneal on-track
quva fda decis pend
end march
afternoon announc motion preliminari injunct quva pharma grant quva enjoin
market releas vasopressin vasostrict conclus trial also file lawsuit
current temporarili stay fda given belief decis put vasopressin categori nomin list
section dqsa drug qualiti secur act unlaw violat act
report full result
guidanc bracket consensu
question cc
close yesterday report revenu ep billion consensu alreadi knew revenu
given preliminari result provid tue origin expect report link
move closer amneal close
leav probabl last stand-alone quarter ipxl ahead anticip deal close creat new amneal
result mix us gener trend continu disappoint across sector pro-forma ebitda outlook littl chang
given strength specialti support new launch outlook year chang rate target move
 sever import updat
et cc thought ahead
report result provid first time guidanc link held call morn print said still
question name around chca growth chci/rx margin outlook confer call associ corpor
present sever import updat bottom line overal guidanc provid comfort especi
given prior week stock weak import take-away us slower growth us consum focu
follow-up call manag shortli
see rel stabil big
surpris new ceo post call
report better late never delay result came thought reason guidanc includ
push pull continu look evid robust growth chca deliv stabl perform
limit stock volatil still make tough argu materi upsid chang outlook target
amneal result consist
expect minor chang
friday market close amneal report full year earn overal surpris result came larg consist
prior public project make minor chang pro-forma forecast also reflect updat result ipxl
continu expect deal close ipxl sharehold meet set
focus week
investor meet travel
aao focu high
meet investor across sever us citi throughout week also host meet
manag mid-west look color aao around pcrx/jnj relationship focu last week high
last week back fundament concern myl/rvnc announc effort collabor
around gener botox limit detail request break-up/sotp analysi high fri suspect strateg
outlook remain focu week final sever small cap specialti name round earn week
amneal report result line expect fri market ipxl sharehold vote
titl link note
closer look sourc overhang
neg impli growth break-up
esmya delay announc competitor pursuit gener botox ad headwind pull last week share
billion market cap shed valuat impli neg growth
add pressur aggress respons keep break-up theme continu highlight relev focu
question manag
ahead meet week
thought
host manag meet come follow pull-back stock sinc late feb high specif driver
behind volatil less clear pipelin debat remain high volatil stock larg unchang last month
trade broad rang sever import pipelin updat expect key product
manag meet focu two
come august
host manag meet mid-west clear theme valu potenti ryanodex eh fulvestr
phase studi path clear set deliv import updat august follow nda file earli
set stage two major catalyst insid month dictat valuat go forward
closer look botox migrain impact
anticip cgrp entri new
cgrp set launch survey neurologist gaug competit threat botox migrain concern impact
valid per survey/analysi think manag key unknown report frame think impact
overal thesi remain link unlock valu base via break-up
straightforward path dsuvia
report focu feedback follow type meet fda review meet minut dsuvia
follow call continu see path refil rel straightforward human factor studi like complet
april addit trial need resubmit approv anticip year-end chang
valu remain pipelin
expect subsi turnaround
insi report provid color though formal guidanc expect around recent complet restructur sale
forc combin recent win remain optimist around stabil effort subsi ahead think valu
pipelin still yet convert minor chang estim chang outlook
launch track still earli
report came number first-tim zilretta launch metric still earli launch appear on-track earli
feedback encourag continu remain one top name low launch expect catalyst-rich pipelin
line extens opportun reiter outperform chang target
dp feedback aao bullish
exparel continu see long runway
growth
sever takeaway american academi orthopaed surgeon aao annual meet past week includ
events/booth tour showcas jnj/pcrx collabor around exparel specif feedback around relationship
encourag importantli still ramp continu see long runway growth around collabor solid earli
feedback chang target outlook
margin big pick-up crl
fda releas updat gener drug review dashboard updat jan link show declin overal
anda applic backlog last caught attent signific pick-up complet respons
letter crl lower anda pend fda period effect send back
industri word watch monthli approv gaug fda product moder recent
agenc activ last progress exist backlog forward
file still materi catalyst year-
agrx report close littl updat pend type meet fda follow twirla meet
request submit plan provid updat follow receipt meet minut agrx expect cash runway
note potenti resubmiss could put approv year-end chang view pend
titl link note
track april xhanc launch
commerci activ alreadi
report result provid busi updat ahead next month launch xhanc nasal polyp commerci
prepar late stage initi sale forc alreadi field posit updat market awar payer
front believ take right step success launch reiter outperform specul risk rate
four topic look
address pro-forma asset sale
share flat ytd recov concern gener botox less two week ago investor
trepid remain tomorrow repres first public opportun ceo address investor sinc look four
topic hope see discuss provid new analysi around valuation/leverag divest mature-co asset
hikma share oversea full year result call focu high given addit new ceo siggi olafsson announc feb
role week earli call london provid cross-read first siggi provid initi sector
outlook follow departur teva ceo global gener medicin group link second heard
healthi messag around facil consolid pipelin ration third latest gener data point
consist unchang eros outlook earli call improv
undergo full strateg review
everi option happen
bia action keep support
stock
chairman ceo brent saunder along new cfo matt walsh week present investor confer earli
afternoon stock nice move move low updat back pre gener botox
concern link period focu far away potenti new strateg messag around possibl
platform revisit preview yesterday four topic look address pro-forma asset sale analysi
move forward strateg evalu
urgenc provid
formal point urgent review strateg option bia action updat analysi look
growth-co mature-co busi provid link prior primer work potenti asset think could divest
bottom line today updat posit continu see valu unlock debat set shift much
question ahead hq
visit manag thought
meet manag headquart next week come interest time look move past
litig headwind gener sector challeng bridg potenti much improv meet
focu need get like remain volatil stock meantim
focus week agn
thesi progress valu
last overhang remov
focu last week far away highest compani announc undertak strateg review urgenc
bia act see report asset sale/break-up analysi link primer pivot prior manag
commentari line thesi focus sinc sept decent push-back opportun
pursu break-up/strateg re-evalu platform could unlock meaning upsid stock last week
low base investor convers last week debat go firmli shift
much actual valu unlock remain op embed upsid potenti
report anticip phase top-line data bupivacain meloxicam er post oper pain
result posit heard sever question morn around level competit differenti versu
magnitud differenti separ post etc continu delv regardless data posit
product move forward competit dynam beyond set becom greater focu
titl link note
materi catalyst
double-digit growth focu shift
morn kmph announc top-line result on-going pediatric/adolesc pk studi part earli act
short durat methylphenid prodrug program expect abus deterr qualiti data suggest predict
oral administr candid patient adhd year age kmph see support singl efficaci
studi establish classroom adhd trial design pediatr without result label limit pediatr patient
remain focus top-line result pivot trial expect mid-year continu see materi upsid kmph
back apadaz pbm/gener partner deal meaning favor pivot data
continu call bigger valu driver
market close symphoni report feb institut sale data million exparel far impli
consensu million importantli symphoni data impli year-over-year growth sell day month
per back forth sequenti growth jan link sell day versu jan last
year growth perspect track higher impli consensu high end
million million rang continu view appropri conserv continu growth seemingli
consist favor feedback partner recent aao confer link overal continu grow
exparel double-digit rate think confid traction continu street number support push higher
take realist view
drill model still struggl view overli ambiti out-year street forecast focu
gener outlook concern around brand assumpt drive growth street model see
follow detail review model consensu lower ebitda put us street reduc
price target
market sell-off fb week seem meaning impact specialti
pharma sentiment mid/larg cap potenti renew visit generalist base investor meet last week
sentiment remain challeng specialist focus lack convict think two reason first
trepid driven macro uncertainti ironi presid trump drug price warn next month came opioid
epidem news confer sector headwind second sens chang improv fundament feel
hold pattern least near-term
morn announc posit result pivot phase trial rimegep oral cgrp receptor antagonist acut
treatment migrain result anticip competit context agn ubrogep trial met co-primari
endpoint pain freedom freedom bothersom symptom hour pivot trial well toler liver
safeti profil similar placebo come sever consider stock result bottom line
data difficult compar appl appl efficaci appear less robust expect come clean liver tox
profil provid competit offer market compar efficaci temper competit
concern around oral cgrp pipelin
investig on-going close still
caught manag today announc investig alleg data integr key deal hurdl
month fre run separ investig major question whether mac-out issu result
debat around likelihood deal close price continu visibl low potenti stock volatil
focus week
report pivot data rimegep
thought follow cc
titl link note
look dynam
sector short interest exhibit period end move lower average/median respect rel
prior period exhibit cover compani took closer look saw sever
larg swing across coverag would also highlight notabl move opioid concern ii kmph
exhibit stock cover glenn novarro brandon henri
titl link note
revenu guid in-lin
buyer weak ktwo remain one stronger growth stori small cap med-tech believ strength
ktwo product portfolio partnership brainlab sale distribut expans continu drive double-digit y/i revenu
growth come year
elekta report revenu gross order adjust ebita result consensu elekta main competitor report
better-than-expect net sale sek fce sek y/i fce adjust ebita sek came
consensu sek gross order book sek fce sek y/i fce elekta instal base
y/i vs separ elekta agreement place mr-linac system
compar previous uniti ce mark still expect function imag avail ce mark subsequ fda
approv track well
busi week orthoped aao
aao hot topic includ hip knee spine robot annual american academi orthoped surgeon aao
confer take place march new orlean focus two key theme confer health
us intern hip knee market respect volum price robot abil drive near medium
term share gain
host cfo brennan vice-president ir susan lisa last week meet increas convict outlook
momentum new product late-stag pipelin coupl steadi progress toward ebit margin goal
enabl maintain one highest growth rate among peer
recent host manag meet ceo kevin lobo reiter outperform rate post meet
increas confid abil maintain posit premium med-tech grower beyond
report result in-line expect two system sold feel senhanc launch gain momentum
compani sold two system includ one system system sale ahead expect
typic take quarter sell robot recal compani receiv fda approv senhanc octob term
distribut compani nineteen sell profession sale funnel progress plan accord
manag outsid compani alreadi announc sale two robot compani six
system place europ perform case
takeaway aao still
driver seat
expect major share gainer knee hip market also posit share captur
tri best limit share loss
question
report present key question ask manag team upcom healthcar confer sever major
confer month march provid question follow compani elgx ew
ktwo
titl link note
med-tech takeaway
earn scorecard strong result compani trade large-cap smid-cap perform well
large-cap compani cover beat revenu compani beat ep smid-cap
compani cover beat revenu strong result lead stock appreci howev coverag univers
saw respect stock increas next trade day believ due prior earn season price-to-earnings basi
med-tech trade premium forward price-to-earnings averag thu one could argu stock price perfect
stock trade follow day provid weak guid respect either organ revenu growth margin
expans ep growth
saturday twelv month result mstop trial present primari endpoint result show
activ monitor via ecg patch rel standard care improv rate diagnosi previous unrecogn atrial fibril
af
jan jan large-cap med-tech ralli howev market sell-off late januari wipe away major
gain ytd large-cap med-tech lag best perform large-cap med-tech stock ytd includ
ew large-cap med-tech hit hardest ytd includ
separ smid-cap med-tech stock perform lag large-cap best perform smid-
cap stock includ ktwo final worst perform smid-cap stock ytd
includ elgx
encor trial show elgx ovat
encor effect custom seal ovat review evid pool retrospect studi six clinic trial
analyz endovascular aneurysm repair use elgx ovat abdomin stent graft studi consist patient us
europ latin america studi standard result across six studi use kaplan-mei surviv estim
order consolid result one packag share physician
takeaway sixth annual day
doc chicago
intermediate-risk label start posit impact tavr procedur volum low-risk next orthoped surgeon reinforc
belief remain driver seat recon consist aao check spine surgeon seen pickup
volum expect pure play spine manufactur continu take share gener surgeon believ surgic robot
infanc robot solut market expand
host roadshow march part capit market healthcar expert seri
wednesday march estimate host doctor dinner new york citi dinner featur structur heart
specialist highest volum tavr center nyc dinner in-depth discuss tavr product
exhibit stock cover frank morgan
titl link note
solid top-line oper
leverag guid ahead
estim rais pt
evhc post solid beat better expect top-line growth cost-reduct initi put place third
quarter miss manag notic confid visibl behind initi guidanc exceed street
flu case declin sharpli
patient visit week
continu see strength acut segment behavior lag pick perform
instanc influenza-lik ill declin patient visit week flu season februari
chart follow page illustr accord cdc weekli influenza surveil report nationwid week
end februari week flu season patient visit due influenza-lik ill ili bp
prior week still exceed nation baselin level week repres second week rapid declin ili
suggest near end sever flu season sinc swine flu epidem note week
level approxim peak level seen last year flu season much milder comparison
decent jv organ hh
volum guidanc consensu
post decent quarter contribut recent solid organ home health volum partial off-set margin
pressur newli acquir locat guidanc exce expect
news nashvil
weekli perspect healthcar
industri compani news valuat
sector price perform week end march healthcar servic stock outperform broader market health
servic select index spsihp lost versu declin behavior
strongest perform subsector last week gain acut hospit gain vs declin prior week manag
gain vs flat perform prior week temporari staf weakest perform subsector last week
note road ndr
abort sale process c-level board chang set somber tone outlook recent
earn call new ceo cindi baier present reason case long-term invest opportun
view lead manag resum
new manag strategi
focus growth
follow-up first glanc note date februari provid addit detail result updat
model incorpor manag guidanc assumpt
follow-up march earn releas provid updat thought estim
pre-releas gener line
improv continu op
gener line street manag expect recov slight miss post decent
volum continu portfolio buck trend among rural hospit peer
acquisit last freestand
latest round vertic integr ci announc agreement acquir esrx cash stock shown ci
sell-off clearli skeptic pay premium struggl franchis manag made reason case
financi strateg merit deal howev investor expect ci next move would instead
given ci commentari around target growth medicar advantag
strong momentum
ad tailwind
ndr typic day steve filton candor compani prospect year ahead along deeper dive
issu highlight earn call take-away simpl remain one favorit name hospit
univers strong momentum thank well-docu flu season along sever known tailwind benefit
titl link note
flu case declin flu season
offici warn flu season could particularli sever prove true activ reach decad high seen
swine flu epidem given sever year flu season believ adjust volum hospit
univers like posit impact although revenu margin flu case lower
model updat steadi perform
freseniu continu benefit solid growth product servic well strong margin recoveri coordin due
partli catch-up payment result larg line expect exclud one-tim item fcpa settlement
charg tax reform benefit earn growth set acceler help tax reform busi manag
remain confid outlook solid normal earn compound-annual-growth-rate high singl digit exclud tax reform
news nashvil
weekli perspect healthcar
industri compani news valuat
week end march healthcar servic stock under-perform broader market health servic select
spsihp gain versu gain skill nurs strongest
perform sub-sector last week gain acut hospit gain vs gain prior week manag
weakest perform sub-sector last week downtick vs uptick prior week
encourag sign challeng
follow-up first glanc note publish updat estim provid addit commentari lower
price target reflect reduc estim acknowledg high leverag cap equiti appreci
add march
strong growth lead
home health hospic footprint
southeast
cloud strateg review
releas medicar advantag part enrol data march ad net member
roll sinc januari bring total enrol membership country-wid increas sinc march last year
reflect increas penetr medicar advantag membership among medicar elig popul year-to-d
membership grown reflect larg bolu new member join roll recent open enrol period
medicar part enrol uptick sequenti increas sinc march last year
view announc acquisit camellia healthcar favor provid solid home health hospic presenc key
certif need con state southeast given oper inpati rehabilit hospit camellia state
ms al la tn believ transact increas compani percentag overlap market prove accret
clinic collabor rate segment recal clinic collabor rate stood year-end
target next two year
evhc lawsuit reveal first snag in-network migrat strategi even eventu resolut favor evhc nt could
potenti impact cash flow concern unh report bloomberg abandon interest pursu
asset evhc believ litig good strateg review process includ bid outright sale
compani believ share lift thursday function prior day sell-off report exit bid
process busi
provid glide path weather macro
gen weak result continu reflect difficult industri trend bigger stori recent restructur significantli
enhanc liquid leverag despit headwind manag encourag sequenti less neg oper
trend focu remain cost reduct portfolio ration restructur macro backdrop stabil
meantim restructur effort date allow weather storm
attract set lt
rais rate outperform
ndr presid ceo paul kusserow cfo scott ginn setup beyond look attract cloud
regulatori uncertainti larg part health sector compani well posit gener strong
organ growth rel sub-sector
titl link note
flu activ continu wind
instanc influenza-lik ill declin patient visit week flu season march
chart page illustr accord cdc weekli influenza surveil report nationwid week end march
week flu season patient visit due influenza-lik ill ili bp prior
week still exceed nation baselin level week repres fifth consecut week declin ili suggest
 near end sever flu season sinc swine flu epidem
pre-released earlier month qhc result consist expect guidanc improv
continu oper increas pt reflect expect de-lever use divestitur proce
news nashvil
weekli perspect healthcar
industri compani news valuat
week end march healthcar servic stock outperform broader market health servic select
spsihp declin versu declin diagnost imag strongest
perform sub-sector last week gain acut hospit gain vs gain prior week manag
gain vs downtick prior week pbm weakest perform sub-sector last week
termin servic agreement
materi reduc cost
view termin spin-off relat servic agreement favor given quorum like captur least
in-sourc servic current provid former parent save repres approxim boost annual
sell-sid breakfast ci/esrx deal
sell-sid updat express script deal manag convict remain strong strateg merit sinc initi sell-off ci
share continu languish sinc announc esrx deal backdrop ci ceo david cordani
esrx ceo tim wentworth host sell-sid breakfast part on-going effort articul strateg vision combin
compani invest commun
news nashvil
weekli perspect healthcar
industri compani news valuat
week end march healthcar servic stock outperform broader market health servic select
spsihp declin versu declin diagnost imag strongest
perform sub-sector last week acut hospit gain vs uptick prior week manag declin
vs uptick prior week pharmaceut distribut weakest perform sub-sector last week
conflict largest sharehold
take-away view agreement glenview posit effect close corpor govern conflict
compani largest sharehold enabl manag focu oper strategi gener earn growth
exhibit stock cover brian abraham
titl link note
remain track pre-nda meet fda lead drug lumateperon given compani comment
may focu format/present data like limit risk outcom though perhap limit visibl
approv potenti overal see good likelihood approv schizophrenia believ luma uniqu profil opportun
across multipl neuropsych indic addit valid readout year underappreci
march toward golo-lin
reiter guidanc compani continu ww infrastructur commerci effort expect
continu impress launch exondi regulatori updat golodirsen yet sens come call remain
acceler approv possibl strong dmd revenu pipelin depth multipl nt catalyst like share
takeaway merg
lane bcrx/idra manag
idra manag team road togeth reiter enthusiasm valu proposit
recent announc merger make case optim capabl assetsha better share handsand
intent long-term goal build stabl opportunist diversifi rare diseas compani continu see argument
merger maintain outperform rate share given favor view benefit/risk
morn partner announc ms drug zinbryta withdrawn world-wide market withdraw
follow report inflammatori enceph meningioenceph ema investig recal essenti split profit
zinbryta
expect continu strong momentum share key readout lead cancer drug selinexor
believ demonstr profil mm dlbcl could enabl acceler approv despit recent appreci believ
valuat especi rel small-cap oncolog compani still fulli reflect selinexor late stage risk profil
market opportun increas tgt reiter outperform
adjust model base recent ms
alzheim stroke develop
updat model reflect recent ms/alzheim s/stroke develop chang valuat continu
see year stabl revenu though believ risk core franchis potenti pipelin growth driver
long-term net-net keep us sector perform -- though acknowledg upside/downsid level given lower adu
expect attract earlier year
new data ph iii studi patient switch viiv triumeq recently-approv biktarvi present croi
show cocktail perform well support potenti biktarvi viabl option patient switch possibl
slightli cleaner safeti howev cocktail look similar differ mean think import
capit perceiv triumeq shortcom abacavir cv baggag dolutegravir liver monitoring/hepatotox
well biktarvi small pill size potenti renal advantag help drive switch market share gain continu believ
valuat underappreci potenti long-term hiv growth pipelin progress
titl link note
morn also develop neuroact steroid post-partum depress announc data pilot studi
iv drug ganaxolon push look expand target enrol due effect size
observ well ahead timelin perspect ph iii iv brexanolon expect
file nda subtl differ agent could possibl impact efficaci believ high
focu given drug similar competitor space believ impend ph ii data
minor overhang share delay push potenti overhang consider could solidifi
lead time though could also mean dataset ultim report robust/interpret earli
interim data expect
highlight visit
manag biktarvi launch high
visit senior manag team discuss clinic busi develop plan depth came meet
feel increas confid near-term posit driversbiktarvi launch nash/inflamm clinic dataa well
long-term competit posit could drive revenu sustain believ start see recent
substanti improv investor sentiment pull stock price increas year
sma pipelin data year
pre-report revenu provid guidanc previous rel unev quarter compani
highlight on-going discuss fda potenti path forward translarna initi data recent report sma
program upcom pipelin day share appreci believ valuat fairli appreci potenti dmd
launch trajectori reward/risk pt model updat
enter busi
heplisav-b launch
expect present initi head/neck updat melanoma pt data abstract addit
on-going launch heplisav-b fulli initi expect gradual first see stabl out-year sale
set valuat floor thu littl credit given io platform see share appreci addit data
worth watch initi
initi outperform rate price target believ pti suit cystic fibrosi cf asset shown promis preclin
signal earli clinic promis despit high competit bar see multipl shot goal success readout
advanc pti potenti captur subset larg cf market
today report fda feedback look support file golodirsen acceler approv base dystrophin though
recent datapoint point direct view confirm strongli posit support likelihood earli expans
exon dmd popul well regulatori amen go forward increas tgt higher po golo still
see appreci potenti share
transit norbert bischofberg
morn ahead investor confer compani earn call later week imdz provid meaning new data
two lead pipelin asset updat last year confer respect believ data
continu support drug like true activ signific improv upon current known standard-of-car treatment --
reaffirm view imdz share current heavili discount ev nearli reflect promis asset
overal io technolog reiter outperform see consider upsid opportun share
announc morn cso norbert bischofberg decid step role end april remain
compani juli departur highli visibl tenur respect leader like norbert
bischofberg certainli loss benefit highli stabl senior manag core believ
long-term success plan anticip eventu expect smooth transit john mchutchison
current evp clinic research respons liver diseas inflamm part oncolog move cso role
andrew cheng current evp clinic research develop oper move newly-cr role
titl link note
morn made first bd deal acquir ph iib-readi asset cognit impair associ
schizophrenia cia total back-load deal valu modest size compani diversif lt growth
take increas import believ deal signal key step emerg strateg direct move
neuropsychiatri expect solid question competit pipelin risk beyond continu street focu
abil augment portfolio later-stag lower-risk asset concret anchor lt stori
announc outcom recent pre-nda meet fda remain track nda submiss
chanc catch compani morn convey recent earn call interact relat
toward process format tabl data present rather explicitli endors result accept mix
late-stag trial outcom see provid direct confirm ph ii data packag lumateperon could
support approv expect continu stock momentum street recogn underappreci lumateperon opportun
celg uniqu situat strong nt cash flow pipelin becom overshadow loom out-year loss
current revenu revlimid cliff caus valuat disconnect base analysi believ one interest value-cr
opportun could go privat would provid upsid current sharehold insul vs medium-term volatil
transit post-revlimid busi model appreci buyer perhap unlik impli valuat floor reiter
morn present pti report faster expect enrol on-going studi enabl nt data
announc new plan test top symdeko could broaden applic add-on success remain
data-rich year data doublet data triplet data though
recent share upsid sinc friday vs see recent initi see room addit appreci
catalyst support cf pipelin opportun
recent top-lin updat data demonstr drug like activ look toward beyond
addit updat pipelin data compani kol event character view highli under-valued asset
especi rel oncolog peer see upsid de-risk catalyst
clinic hold compet
increment posit
today market close announc clinic hold ignit dmd studi studi evalu
aav-bas microdystrophin gene therapi treatment duchenn muscular dystrophi dmd place hold first
patient dose clinic trial experienc unexpect seriou advers reaction within day administr drop
platelet count reduct red blood cell complement activ recal also earli clinic test microdystrophin
gene therapi program dmd
remain track key data selinexor readout year larg heme/onc indic solid tumor plan continu
evolv well continu like upside/downsid given selinexor potenti market opportun prior mm dlbcl data
would remain buyer share
compani updat cf portfolio timelines/plan report year-end cash balanc earlier yesterday earn
pr contain new surpris pti remain set activ year poc catalyst refin overal profil cf
portfolio believ provid multipl opportun add stock upsid reiter outperform
titl link note
overhang though like
view competit data ozanimod
ms franchis continu hold tight
pull
yesterday press confer opioid epidem presid trump pledg unveil host new polici propos aim
lower prescription-drug cost sometim next month announc scant detail hint drug
lobbi complex distribut system partli blame could target vs drugmak believ white hous
recent white paper review key point may also offer clue notabl take consider innov
strongli overal sens investor toler drug price rhetor improv continu believ realist
chang like modest impact nonetheless anticip could creat somewhat near-term overhang particularli
large-cap name within group valuations/senti tie medium-term product perform rather
last night arena report data modul etrasimod show gener compar efficaci celg ozanimod
ozanimod remain much along believ celg current valuat alreadi discount potenti regulatori risk
increas competit key pipelin drug ozanimod continu see multi- potenti ozanimod ibd ms
continu see consider appreci potenti celg provid execut nt regulatori clinic commerci
front help turn sentiment around
surpris announc founder/ceo dr randi schatzman step immedi navig key
entrant novel class incept ph iii leav aldr well-posit well-capit ip issu see
potenti new leadership regulatory/commerci experi help de-risk eptinezumab file launch
process perhap fresh perspect might also help bridg gap see epti oppti aldr current
believ ms franchis perform solidli rbc/con fy estimate yoy incl ocrevu rel
stabl treatment dynam especi light recent competit setback longer term though continu believ could
import brand gener competit pressur share price end note two novel treatment recent
emerg data stem cell transplant btk inhibit could worth watch highlight evolv landscap given
complex potenti side effect sct unlik major immedi competit threat though outstand efficaci albeit
small studi could make option refractori pt otherwis tysabri ocrevu continu view valuat
fairli balanc near term stabil ms franchis strong neurosci platform risk accompani
depend aducanumab growth need addit pipelin expans
markman brief on-going gener revlimid litig drl due tomorrow provid addit clue potenti
strength parti argument go upcom markman hear like mid-year believ celg favor
posit litig markman put favor negoti posit settlement decreas
concern earli revlimid gener risk drive upsid
aldr share weak sinc announc founder/ceo dr randi schatzman departur earlier week believ
mostli due concern timelin bla file lead drug eptinezumab specif re-affirmed press
releas convers compani believ rais concern may delay issu
assembl file packag follow commun believ specif issu identifi
seem like incom ceo await deeper dive compani oper reiter specif file
titl link note
takeaway chicago day car-
cf ms
rbc healthcar team host doc day chicago includ kol cf ms car-t came impress vrtx
symdeko launch solid studi could enrol rapidli someth still fulli appreci vrtx valuat
sens physician dynam could posit impact long-term sustain ms franchis though await viabil
growth driver get construct re-affirmed view gradual uptak substanti long-term potenti car-t
celg key program
celg drl reach surpris
sinc data competitor arena modul etrasimod report earlier week receiv mani question
competit landscap celg ozanimod follow addit analysi aim better contextu rel dataset view
remain long-term competit landscap among oral ibd drug like crowd includ jak modul
market larg recently-upd penetration/sal number ozanimod peak prob-adjust ibd ms alreadi
reflect continu see mani opportun sentiment multipl improv celg come month includ
ozanimod rtf clariti car-t updat
note thursday markman brief on-going celg dr reddi gener revlimid litig due lead much-
anticip markman hear expect would set celg favor settlement much surpris newly-emerg document
friday night found indic celg drl resolv differ around disput claim term agre markman
hear need see posit indic settlement approach continu believ settlement gener
filer increment out-year revlimid econom provid reassur unlik earlier-than-expect gener revlimid
entrant/cliff see single-digit stock upsid weekend posit step
despit recent upsid like setup upcom data given low bar head/neck cancer
evid activ prior trial studi similar drug increas po floor around mid-teen heplisav alon given
long tail continu temper heplisav launch expect anticip potenti upsid data trial look
initi data gild easl abstract assess single-ag combo data nash compon show continu potenti
activ well combin notabl safeti signal abstract increment de-risk pipelin program believ
multi- opportun receiv littl credit though caveat interpret short biomarker/imaging-driven studi
inconsist like due small sampl size non-definit endpoint see posit step continu expect
appreci potenti renew enthusiasm valu base hiv busi emerg pipelin area like
exhibit stock cover kennen mackay
titl link note
download model updat
bracket estim
nerlynx revenu line street estim guidanc encompass estim see
guidanc report street consensu revenu achiev await guidanc continu chmp
interact eu defin path forward becom construct opportun stock
updat model us tax reform pt
 continu like ahead
updat model account us tax reform tax vs prior increas pt remain one
prefer smid-cap name see potenti addit upsid upcom peanut allergi sever asthma read-
out updat upside/downsid detail note despit stock recent run data-set
full palisad present aaaai
continu demonstr
efficaci safeti
present full result palisad studi aaaai weekend follow analyst event aaaai
present reinforc unambigu efficaci result potenti provid prescrib patient famili certainti
peanut protect patient toler oppos less robust ambigu protect seen
competitor physician feedback aimt-host panel unanim posit note data practice-chang
signific interest patient parent follow public releas posit data taken togeth view full
present reinforc bullish stanc competit profil commerci prospect see palisad top-lin
takeaway pt increas await addit data rams real-world safeti toler studi palisad
follow-on studi ahead us bla file
continu one prefer smid-cap name ahead sever adult peanut allergi data march
eosinophil asthma data
releas late-break abstract titl weekend american colleg cardiolog confer confirm data
odyssey cv cardiovascular outcom studi antibodi praluent present praluent approv
current market repatha cholesterol lower therapi seen mortality/cv event
fourier outcom trial repres first look odyssey outcom trial importantli odyssey
number trial design differ vs competitor fourier trial though anticip larg similar result rel
risk reduct major cv event littl benefit hospit cv-relat mortal repres base-
case situat antibodi remain larg undifferenti efficaci perspect
earn download model
odyssey like show similar
odac vote favor blincyto
mrd could open door larger
today fda odac panel vote favor blincyto benefit/risk profil patient cr minim residu diseas
posit mrd vote question explicitli ask whether blincyto approv indic though base
physician commentari ye vote seem interpret vote approv except one physician panelist
point discrep view overal sentiment relay vote posit blincyto approv prospect
issuanc new camsyl formul
morn announc uspto provid notic allow patent applic cover high
dosag strength rubraca camsyl formul includ commerci avail dosag strength
importantli issuanc patent extend rubraca ip runway us
takeaway post-aaaai
conduct kol call discuss palisad data present aaaai confer overal kol came away
aaaai confer impress efficaci safeti unexpectedli lower vs histor oit trial saw
foundat futur combo biolog howev academ center-bas kol cautiou toward roll-out
within privat practic set note potenti requir addit staff physic space key takeaway
pleas see transcript pg onward detail
titl link note
catalyst-rich establish obsv
leader women health
continu see catalyst-rich year obsv upsid potenti endometriosi top-lin regulatori
path forward live birth follow-up data nolasiban
odyssey win class
weekend american colleg cardiolog meet partner sanofi present posit data praluent odyssey
outcom studi studi achiev primari endpoint rel risk reduct major advers cardiac event mace
anticip upsid surpris all-caus mortal hr nomin view posit
competit commerci prospect though lack statist signific mortal benefit creat uncertainti surround
potenti label inclus anticip could trade data weak view data
meet best-cas upsid scenario odyssey preview repres stat-sig mortal
continu like addit rams data bolster valu proposit
year
rarx remain track pnh trial start focu shift potenti regulatori requir pivot
post-acc catch call takeaway
follow present parluent odyssey outcom data see note conduct kol call discuss recent
praluent odyssey outcom data kol impress data note achiev primari mace endpoint
larg anticip though surpris patient popul lower absolut risk anticip base enrol criteria
vs fourier trial effect extent down-titr therapi due low level trial design
hit hurdl pnh
downsid limit ahead
trial read posit remov downsid debat like continu ahead next trial given narrow statist
signific miss morn releas posit top-lin result trial vs soliri naiv pnh patient slightli
ahead expect data demonstr non-inferior studi object numer improv
across co-primari endpoint transfus avoid normal ldh well secondari endpoint
risk larg independ
rpdd set stage
snda submiss cabo
set stage potenti launch
clinic hold read-through program yesterday announc clinic hold
base program dmd caus sell-off sever gene therapi name also leverag vector
see yesterday clinic hold solid program class effect neg read-through program mp abo-
cln dose first patient lower vg/kg dose result decreas platelet red blood cell
count well evid complement activ howev note follow caveat lead us believ causal
ae signal capsid see exhibit comparison gene therapi program
morn announc submit snda cabo base celesti result see top-lin
takeaway gi takeaway line manag guidanc file set stage potenti launch
assum prioriti review recent host manag healthcar confer see takeaway
manag reiter cabo launch top prioriti prepar underway continu like cabo market
opportun remain immatur market due limit use soc system therapi nexavar stivarga limit use
system therapi larg due patient appropri transit care medic oncologist receiv
chemo-embol care intervent radiologist
titl link note
npdr market remain commerci
show stori
posit panorama data form basi sbla moder sever sever npdr though commerci uptak larg
earlier stage market remain key question morn announc eylea met primari endpoint panorama
studi moder sever sever non-prolif diabet retinopathi npdr patient eylea-tr patient
experienc greater improv baselin diabet retinopathi sever scale drss vs placebo-tr
patient panorama data provid rational earli intervent patient prior progress macular
edema though anticip commerci uptak set could remain challeng given patient may choos postpon
treatment vision loss experienc upon progress macular edema
adcetri approv stage iii/iv hl
adcetri receiv label stage iii/iv hl line expect though potenti restrict vs expect line
prioriti review advanc hl could enabl use stage iib patient focu commerci execut
updat us financi guidanc guidelin inclus clinic mileston potenti readout trial
increas pt celg neurosci
collabor ahead key catalyst
see prta/celg neurosci collabor ad non-dilut fund key partner earli stage pipelin see
extern interest ad valid discoveri engin provid addit downsid protect ahead
pronto read-out mid-year updat model reflect celg cash equiti invest increas pt
pipelin remain upsid pt
increas pt mirvetuximab
combo opportun ahead key
upcom mirvetuximab keytruda dose-escal data sgo could provid initi indic combo synergist activ
synergist orr could lead upsid given potenti combo broadli use earlier line recurr platinum-
resist ovarian cancer vs downsid share trade back level pre-rec run efficaci signal
signific room growth remain mainten oc current decis make support rubraca use upon approv
parpi ovarian cancer oc mainten market remain larg untreat suggest potenti signific growth howev
lynparza appear current agent choic among survey physician surprisingli survey respond note lynparza
efficaci well toler drove choic agent clinic treatment decis make continu like
rubraca mainten ahead april pdufa anticip drug competit safety/efficaci profil enabl
captur signific share remain market move forward look sgo confer weekend gain
qualit parpi color surround decis make detail quantit survey
kol saw io adc soon-to-be-approv favorit tnbc like parpi brca mbc less enthusiast toward pbyi
nerlynx extend adjuv mbc favor cleaner therapi
posit chmp opinion set stage
today posit oc treatment chmp opinion open door small market opportun importantli expedit rubraca
mainten eu approv use variat review vs standard review bring rubraca
lucr eu oc mainten market closer competitor azn tsro
win em chmp win
repatha biosim herceptin
morn receiv posit chmp decis kanjinti biosimilar herceptin inclus cv outcom data repatha
label withdraw aranesp label expans treat anemia md patient
activ sgo
mirv pembro combo efficaci beat expect orr fr heavili pre-treat proc like combo safeti
profil convers sgo suggest gi safeti signal due diseas burden patient vs drug-rel anticip
could trade impress data remain buyer
titl link note
ev btd add valid
acceler approv path
morn announc enfortumab vedotin ev receiv breakthrough design btd advanced/metastat
urotheli cancer previous treat checkpoint inhibitor cpi recal ev current potenti registr
monotherapi trial set well trial combin cpi post-platinum/platinum-inelig patient though
btd monotherapi program see today fda btd ad regulatori valid ev potenti path forward
acceler approv pathway on-going trial
 increas pt guidanc
reiter timelin read-out oraxol mbc second interim ak provid near-term catalyst
signific upsid potenti continu like catalyst pipelin updat model reflect revenu
guidanc expect increas pt
updat add question synergist
top-lin add question buy
dataset topacio zejula pembro proc mediola lynparza durva psoc suggest potenti addit benefit
though magnitud unclear question potenti synergi move forward despit promis pre-clin data
adult peanut allergi data introduc question answer though continu like upcom
data asthma anticip see biolog link diseas etiolog support posit outcom
exhibit stock cover georg hill stephen hagan
titl link note
moder januari
iqvia wholesaler-level gener price data januari show moder volume-adjust gener deflat y/i
signific improv deflat suppli chain weather addit brand inflat return
normal januari decemb impli manufactur may taken price increas earli
deceler gener drug price signific conclus data point gener market conform
character suppli chain execut increas confid visibl
bottom expect
challeng come
patterson report larg ep miss vs consensu guid ep midpoint impli
deterior remain cautiou follow result wait stabil oper metric
consid becom posit
fear rain rare come
investor fear biopharma consolid spell troubl pharma servic compani recent receiv influx call
investor concern larg cap pharma compani potenti impact pharma servic name
move drug rebat poc
unitedhealth group today announc new pharmaci benefit design function risk group allow drug manufactur
rebat share adjud beneficiari point care see chang pr relat oppos
actual chang pbm market
 epic take least part
epic announc select singapor nation govern ehr vendor countri nation
electron record remain unclear whether sole-sourc award split award seen notif
singapor health system view modest neg allscript believ investor expect either allscript
win split contract includ allscript epic
post slide present invest commun meet host annual himss confer
compani rais forecast long-term revenu growth rate midpoint prior forecast
midpoint larg reflect addit va opportun long-term growth rate later
present indic still activ work contract closur va believ inclus va contribut
long-term growth rate indic high degre confid contract close
analyst day himss
view updat invest commun meet mix posit neg posit
includ increas revenu growth target lt forecast off-set reduct annual margin expans forecast
indic core weak
report stalk
jone report advanc talk acquir express script deal potenti announc earli
today thursday view transact line vertic integr thesi esrx highli attract asset
last pbm asset scale recent upgrad esrx share cite deal option key part thesi note esrx would
make attract deal partner
pbm jenga pull apart
report take close look custom concentr insid caremark pbm busi key take-away
caremark identifi client defect risk relat aetna transact figur believ manag
posit implic procur singapor follow decis singapor ministri
use two emr countri
titl link note
 old compani
walgreen today announc departur cfo georg fairweath jame keho cfo takeda pharmaceut co
would replac effect june mr fairweath long tenur season veteran believ known
conservat insid wba bold creativ cultur stay senior advis ceo stefano pessina busi develop
financ prior join takeda mr keho serv cfo kraft food financ director greater china japan
allergan believ mr keho intern experi consum good healthcar enabl draw use
perspect new role
desert oasi note pbmi
desert pbmi recent attend pbmi confer trade event focus pharmaci benefit administr
prior year confer focus econom structur pharmaci benefit year much focu ethic
benefit especi given soar brand specialti drug price key point discuss sever session rapidli
grow gross-to-net spread brand specialti drug drive higher level rebat manufactur though driven
smaller number product
new
attend annual himss confer recent spent two day annual himss healthcar confer found tone
confer subdu prior year make sens given industri seem fulli lap
spend relat high-tech regulatori requir mani vendor must fulli embrac return-driven spend environ
felt biggest buzz around new kid himss block amazon googl salesforc much larger
presenc year confer vendor booth abuzz prospect receiv demo
acquir esrx
posit deal esrx view sale good outcom esrx sharehold consist view
vertic integr healthcar servic space leav pt evalu deal structur ci share price
potenti bidder emerg
fda finish sprint fda releas updat gener drug review ye report decreas total
applic backlog addit number applic fda decreas
number applic back hand applic increas work- driven increas approv
quarter y/i increas complet respons commun applic describ defici
applic fda continu work backlog clear drug market may pressur price start
show sign moder
let disrupt begin caremark
pbm
million member government-sponsor healthcar program announc made
invest rxadvanc small tech-en pbm estim one caremark largest pbm custom
revenu pbm revenu
circuit train round
benefit consult ci/esrx
benefit consult nervou ci/esrx cvs/aet follow cigna/express script transact announc
touch base sever pbm consult attend benefit event abl take temperatur market
consult steer variou type pbm busi within risk book consult gener saw churn risk esi book busi
oppos caremark book consult client tend believ alreadi done good job wall pbm
busi segment
retail-level script volum flat
februari weaken flu season
retail level flat februari iqvia npa retail-level prescript data februari show volum remain flat y/i basi script
retail mail volum remain flat flat volum indic tailwind strong flu season
behind suppli chain data repres modest neg suppli chain given flu season typic continu februari
titl link note
come va contract
view report regard potenti chang top va risk yet sign ehr contract chanc
new va secretari could choos go differ direct depart instead full ehr replac
order adjust model
view unchang maintain outperform rate price target comment recent va leadership news
report adjust model better reflect quarterli progress ep line expect season
pressur drug suppli chain
thought price action/senti
politico report hh secretari azar remark today state trump administr releas plan address high drug
price within week said propos would focu pbm discount negoti pharmaceut
manufactur remark includ prais pbm pass along rebat patient point sale suspect plan
administr could includ push requir medicar part plan pass along rebat patient point sale
believ would impact pbm financi medicar part underwritten product pbm would adjust medicar part
premium reflect lower share rebat kept plan also note propos along line new
gener well understood within industri
disrupt medium-term uncertainti drive sell drug suppli chain share continu sharpli under-perform market
investor anxieti seem palpabl mani name believ investor perceiv unpreced risk busi model
realign disrupt lead indiscrimin sell drug suppli chain share risk extern trump/azar nfp
hospit google/verili amazon direct amzn/bh/jpm drug price regulatori intern unh/optum cvs/aet ci/esrx lead
investor question success busi model futur earn return profil
mile note news
sentiment improv face face wrote day terribl investor sentiment drug suppli chain
improv recent day market meet addit drug suppli chain pessim investor resist
commit fresh fund hcit space believ pessimist healthcar gener discuss long list reason
cautiou healthcar servic name near medium term investor pile fear feder budget process risk well mid-term
presidenti elect risk reason greater discount appli healthcar space
exhibit us med-tech spec pharma coverag valuat tabl
appli growth rate base number arriv data
price uk time march
pricemcapevev/salesforecast growthev ebitdaforecast growthpeforecast growthloc currencyloc compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate bax-ussector dickinson companybdx-ussector corporationbsx-ustop wmgi-usoutperform spec biomet itgr-ussector lifesci iart-ussector group hold trxc-usoutperform spec aray-ussector surgic isrg-ussector medic systemsvar-ussector ops-caoutperform spec riskcad tos-casector perform spec riskcad med-tech pharmaacelrx pharmaceut acrx-usoutperform spec therapeuticsagrx-usoutperform spec akrx-ussector depo-ussector perform spec pharmaceut endp-ussector therapeuticsflxn-usoutperform spec laboratoriesipxl-ussector therapeuticsinsy-usoutperform spec pharmaceut spec spec prgo-ussector performila spec pharma exhibit us biotech coverag valuat tabl
price uk time march
pricemcapevev/salesforecast growthforecast growthforecast growthloc currencyloc compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate vrx-ussector perform dvax-usoutperform spec risk sino-usoutperform spec risk ptct-ussector perform nologypbyi-ussector perform spec risk srpt-usoutperform onc-caoutperform spec riskcad nvln-ussector perform spec risk life scienc pli-caoutperform spec riskcad saabvx-froutperform spec risk saup-caoutperform spec riskcad once-usoutperform spec risk abeo-usoutperform spec risk biopharmaceuticalsaldr-usoutperform perform sbcrx-usoutperform spec risk na na na biib-ussector perform celg-ustop pick senta-ussector perform nvglpg-nlsector perform sciencesgild-usoutperform design imdz-usoutperform spec risk corporationincy-usoutperform sicpt-usoutperform therapiesitci-usoutperform spec risk kpti-usoutperform spec risk mrus-ussector perform spec risk pti-usoutperform spec risk sage-usoutperform svrtx-usoutperform pharmaxlrn-ussector perform sagio-usoutperform aimt-usoutperform spec risk akba-ussector perform salxn-usoutperform amgn-ussector perform spec risk atnx-usoutperform bmrn-ussector perform bivv-ussector perform clvs-usoutperform prime fprx-usoutperform spec risk saobsv-usoutperform spec risk prta-usoutperform spec risk srarx-usoutperform spec risk sregn-ussector perform geneticssgen-usoutperform perform ebitdapestocktickerr exhibit us healthcar servic healthcar technology/distribut coverag valuat tabl
note dr aet evhc knd qhc qsii appli growth rate base number arriv data
price uk time march
